Ipramol (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic (M3) receptors on airway smooth muscle, preventing acetylcholine‑induced tightening. Salbutamol stimulates β2‑adrenergic receptors, raising cyclic AMP levels and causing smooth‑muscle relaxation. The dual action yields additive bronchodilation, easing breathing in obstructive airway conditions.

The dose of Ipramol is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Healthcare professionals select the appropriate strength, frequency, and route of administration according to clinical guidelines.

Safety data for ipratropium bromide and salbutamol in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under the guidance of a qualified healthcare provider.

To order Ipramol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Ipramol combines an anticholinergic (ipratropium) with a β2‑agonist (salbutamol), offering broader bronchodilation than either component alone. Compared with single‑agent inhalers, the combination can provide faster symptom relief and may reduce the need for higher doses of individual agents, though cost and device preference also influence choice.

Store Ipramol at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed when not in use.

Ipramol is delivered by inhalation using a metered‑dose inhaler or nebulizer, and may also be available in oral form for specific formulations. Patients should follow the inhalation technique instructed by their healthcare provider to ensure optimal drug deposition in the lungs.

Serious adverse events include paradoxical bronchospasm, significant tachycardia or arrhythmias, and severe allergic reactions such as anaphylaxis or angioedema. Patients should seek immediate medical attention if they experience worsening breathing, rapid heartbeat, or signs of an allergic response.

Ipramol is contraindicated in individuals with known hypersensitivity to ipratropium, salbutamol, or any excipients. It should also be avoided in patients with narrow‑angle glaucoma, severe cardiovascular disease, or those who have experienced a prior paradoxical bronchospasm with similar agents.